Thyrocare Technologies shares fell sharply, declining around 8%, after the company's promoter Docon Technologies sold approximately 1.58 crore shares in a block transaction.

The divestment reduced Docon Technologies' holding in Thyrocare Technologies from 60.92% to 51.02%. Despite the reduction, Docon Technologies remains the promoter and holding company of the diagnostics firm. Docon Technologies is affiliated with API Holdings, the parent of online pharmacy platform PharmEasy, which acquired a controlling stake in Thyrocare in 2021 in one of the healthcare sector's notable cross-platform consolidation moves.

Thyrocare Technologies is one of India's leading diagnostic and preventive healthcare service providers, offering a wide range of pathology and radiology tests. The company operates on a hub-and-spoke model centered on a high-throughput automated laboratory, processing large test volumes at competitive price points — an approach that distinguishes it from peers focused primarily on walk-in clinic collections. The company is listed on Indian stock exchanges and operates a network of laboratories and collection centres across the country.

The sell-down by the promoter comes amid continued activity in India's diagnostics sector, where companies including Dr. Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostic Centre, and Krsnaa Diagnostics also compete for market share. The sector has been undergoing gradual consolidation as larger chains expand into tier-2 and tier-3 cities and digital health platforms increasingly integrate diagnostics into their service offerings.

Thyrocare Technologies recently reported a net profit of Rs 240 crore for the first quarter of FY27, representing a 34% increase year-over-year, according to ET HealthWorld.

Source: Economic Times Markets